Skip to content
Maravai LifeSciences Holdings, Inc. logo

Maravai LifeSciences Holdings, Inc.

MRVI

Maravai LifeSciences is a life sciences company that provides specialized products and services essential for the development of drug therapies, vaccines, and diagnostics.

Market cap
$986.82M+184%
Revenue$204.7M-15.4%
Net income-$104.6M+35.7%
Free cash flow-$52.6M-283%
EPS (diluted)-$0.71+37.7%
Trailing twelve months · change vs. prior year

Earnings

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$48.7M
EPS estimate-$0.05

Financials

Q1 2026

Income statement

See full
Revenue$65.8M+40.5%
Gross profit$33.7M+336%
Operating income-$2.2M+95.6%
Net income-$3.7M+87.5%
EPS (diluted)-$0.02+90.5%

Balance sheet

See full
Cash & equivalents$165.9M-41.8%
Total debt$270.9M-17.1%
Total equity$211.6M-29.6%
Total assets$713.2M-25.7%

Cash flow

See full
Operating cash flow$8.7M+192%
CapEx$4.4M-1.4%
Free cash flow$4.2M+130%

Valuation & ratios

Valuation

See full
Market cap$986.82M+184%
Enterprise value$1.09B+126%
P/S4.8×+3.1×

Profitability

See full
Gross margin29.3%-8.0pp
Operating margin-82.2%-16.6pp
Net margin-51.1%-9.9pp
FCF margin-25.7%

Returns & leverage

See full
Return on equity-40.8%-4.0pp
Debt / equity1.3×+0.2×
Current ratio5.9×-0.1×

Segments

By geography

See full
North America$35.7M+21.9%
Europe, the Middle East and Africa$21.9M+219%
Asia Pacific$7.9M-25.4%
Latin and Central America$329.0K+125%

Competitors

Profile

Maravai LifeSciences is a life sciences company that provides specialized products and services essential for the development of drug therapies, vaccines, and diagnostics. The company focuses on enabling biopharmaceutical research and production through high-quality nucleic acids and protein detection solutions.

Competitive position

A leading provider of specialized nucleic acids and impurity testing reagents for the biopharmaceutical industry.

GeographiesGlobal
Customer segmentsBiopharmaceutical companies, Academic research institutions, Diagnostics companies
Business modelDirect-to-customer manufacturing, B2B product sales
SuppliersChemical raw material suppliers, Specialized laboratory equipment manufacturers
CustomersDrug developers, Vaccine manufacturers, Clinical diagnostic laboratories
Listed2020
Employees570.0
CEOBernd Brust
FilingsSEC EDGAR

Questions, answered.

What is Maravai LifeSciences Holdings, Inc.'s market cap?
Maravai LifeSciences Holdings, Inc. (MRVI) has a market capitalization of $986.8M and trades on NASDAQ.
What is Maravai LifeSciences Holdings, Inc.'s revenue and profitability?
Maravai LifeSciences Holdings, Inc. generated $204.7M in trailing twelve-month revenue with a net loss of $104.6M, representing a net margin of -51.1%. Gross margin stands at 29.3%, with free cash flow of -$52.6M. These figures are based on the Q1 2026 filing.
Who are Maravai LifeSciences Holdings, Inc.'s competitors?
Maravai LifeSciences Holdings, Inc.'s key competitors include Danaher Corporation, Thermo Fisher Scientific, Repligen Corporation, and others. These companies compete in similar markets and product categories.
What subsidiaries does Maravai LifeSciences Holdings, Inc. have?
Maravai LifeSciences Holdings, Inc.'s subsidiaries include TriLink BioTechnologies, Cygnus Technologies.
Where is Maravai LifeSciences Holdings, Inc. headquartered?
Maravai LifeSciences Holdings, Inc. is headquartered in United States of America and employs approximately 570 people. It has been publicly traded since 2020.